Search Results

265 results

  1. TSRC, Tob. Sci. Res. Conf., 2021, 74, abstr. 32

    Development of recommendations of descriptive consumer-reported outcome measures (descriptive-CROM) and related definitions in tobacco and nicotine research

    WEI L.(1) on behalf of CORESTA CROM Task Force: CLERC E.(2); SHETTY M.(3); CHREA C.(2); PRASAD K.(3); SARKAR M.(1)
    (1) Altria Client Services LLC, Richmond, VA, USA; (2) Philip Morris International, Neuchâtel, Switzerland; (3) British American Tobacco, Southampton, UK
    Background: The Consumer Reported Outcome Measures (CROM) Consortium Task Force (TF), consisting of academic researchers and members from various tobacco companies, was formed within the Cooperation Centre for Scientific Research Relative to Tobacco...
  2. TSRC, Tob. Sci. Res. Conf., 2021, 74, abstr. 42

    Chemical characterization of e-vapor products using non-targeted analysis by gas chromatography mass spectrometry

    NOE M.R.; SHAH N.H.; MILLER J.H.; AGNEW-HEARD K.A.; GARDNER W.P.
    Altria Client Services, Richmond, VA, USA
    The Premarket Tobacco Product Applications (PMTA) guidance issued by the FDA for Electronic Nicotine Delivery Systems (ENDS) recommends that in addition to reporting specific harmful and potentially harmful constituents (HPHCs), manufacturers...
  3. TSRC, Tob. Sci. Res. Conf., 2021, 74, abstr. 45

    Compound identification process for GC-MS non-targeted analysis of JUUL aerosol using a custom mass spectral library

    JEONG L.N.(1); NOE M.R.(2); SHAH N.H.(2); CHAKRABORTY S.(2); MILLER IV J.H.(2); GILLMAN I.G.(1)
    (1) JUUL Labs, Inc., 1000 F Street NW, Washington, DC 20004, USA; (2) Altria Client Services LLC (a Service Provider to Juul Labs, Inc.), 601 East Jackson St, Richmond, VA 23219, USA
    The FDA’s Premarket Tobacco Product Application (PMTA) guidance for Electronic Nicotine Delivery Systems (ENDS) recommends that applicants evaluate unique constituents in the aerosol of ENDS products for potential health risks. There is a need for...
  4. TSRC, Tob. Sci. Res. Conf., 2021, 74, abstr. 69

    Human abuse liability assessment of tobacco and nicotine products: considerations to meet current regulatory recommendations

    VANSICKEL A.(1); BAXTER-WRIGHT S.(2); CAMPBELL L.(2); SHERWOOD N.(3); KONG M.C.(4)
    (1) Altria Client Services, Richmond, VA, USA; (2) RAI Services Company, Winston-Salem, NC, USA; (3) Neil Sherwood Consulting, Nyon, Vaud, Switzerland; (4) Altasciences, Overland Park, KS, USA
    The U.S. Food and Drug Administration (FDA) recommends that tobacco product manufacturers provide information regarding the abuse liability of tobacco and nicotine-containing products to support pre-market tobacco, modified risk tobacco product and...